 |
 |
 |
 |
 |
Glibenclamide
Several groups have investigated the role of a variety of K + channels in oxygen-induced vasodilatation and pulmonary vascular tone in the fetal and perinatal pulmonary circulations and some of these investigations have yielded different results, in some cases in different species. Cornfield et al. 1996 ; reported that TEA and ITX attenuated, while glibenclamide had no effect on.
Table 2 Prevalence Of Cognitive Impairment Neuro, Mixed, and General Population ; Neuro Pain 11.4% Mixed Pain 6.4% General Popu~1.
Dr robert spiegel, chief medical officer of schering-plough, said: the prescription status of these medications is necessary to protect and optimise public health and glucovance.
GLIBENCLAMIDE INHIBITS ISLET CPT-1 29. McGarry JD. Banting lecture 2001. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51: 718, 2002. Metz SA and Dunlop M. Production of phosphatidylethanol by phospholipase D phosphatidyl transferase in intact or dispersed pancreatic islets: evidence for the in situ metabolism of phosphatidylethanol. Arch Biochem Biophys 283: 417428, 1990. Ozanne SE, Guest PC, Hutton JC, and Hales CN. Intracellular localization and molecular heterogeneity of the sulphonylurea receptor in insulin-secreting cells. Diabetologia 38: 277 282, Prentki M, Joly E, El-Assaad W, and Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in betacell adaptation and failure in the etiology of diabetes. Diabetes 51, Suppl 3: S405S413, 2002. 33. Prentki M, Vischer S, Glennon MC, Regazzi R, Deeney JT, and Corkey BE. Malonyl-CoA and long chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion. J Biol Chem 267: 58025810, 1992. Regazzi R, Li G, Ullrich S, Jaggi C, and Wollheim CB. Different requirements for protein kinase C activation and Ca2 independent insulin secretion in response to guanine nucleotides. J Biol Chem 264: 99399944, 1989. Renstrom E, Barg S, Thevenod F, and Rorsman P. Sulfonylurea-mediated stimulation of insulin exocytosis via an ATPsensitive K channel-independent action. Diabetes 51, Suppl 1: S33S36, 2002. 36. Rorsman P, Berggren P-O, Bokvist K, and Efendic S. ATPregulated K channels and diabetes mellitus. NIPS 5: 143147, 1990. Rubi B, Antinozzi PA, Herrero L, Ishihara H, Asins G, Serra D, Wollheim CB, Maechler P, and Hegardt FG. Adenovirus-mediated overexpression of liver carnitine palmitoyltransferase I in INS-1E cells: effects on cell metabolism and insulin secretion. Biochem J 364: 219226, 2002. Sjoholm . Aspects of novel sites of regulation of the insulin stimulus-secretion coupling in normal and diabetic pancreatic islets. Endocrine 9: 113, 1998. Sjoholm , Zhang Q, Welsh N, Hansson A, Larsson O, Tally M, and Berggren P-O. Rapid Ca2 influx and diacylglycerol synthesis in growth hormone-mediated islet -cell mitogenesis. J Biol Chem 275: 2103321040, 2000. Thams P, Hansen SE, Capito K, and Hedeskov CJ. Role of glucose metabolism and phosphoinositide hydrolysis in glucoseinduced sensitization desensitization of insulin secretion from mouse pancreatic islets. Acta Physiol Scand 154: 6574, 1995. Tian Y-M, Johnson G, and Ashcroft SJH. Sulfonylureas enhance exocytosis from pancreatic -cells by a mechanism that does not involve direct activation of protein kinase C. Diabetes 47: 17221726, 1998. Wollheim CB and Biden TJ. Second messenger function of inositol 1, 4, 5-trisphosphate. Early changes in inositol phosphates, cytosolic Ca2 , and insulin release in carbamylcholinestimulated RINm5F cells. J Biol Chem 261: 83148319, 1986. Yaney GC, Korchak HM, and Corkey BE. Long-chain acyl CoA regulation of protein kinase C and fatty acid potentiation of glucose-stimulated insulin secretion in clonal -cells. Endocrinology 141: 19891998, 2000. Zhou YP, Ostenson CG, Ling ZC, and Grill V. Deficiency of pyruvate dehydrogenase activity in pancreatic islets of diabetic GK rats. Endocrinology 136: 35463551, 1995.
Results-the test drugs were dosed as follows: 100 mg acarbose a ; three times a day, 1 placebo tablet three times a day, 5 mg glibenclamide tablets dosed 1-0-0 or 1-0-1, mean dose 3 mg day and inderal.
SLIDE 13 A total of 4209 asymptomatic patients with FPG of 108 to 270 mg dL entered the UKPDS Glucose Control Study. Patients were stratified by IBW. Of those patients with body weight 120% IBW, 342 were randomly assigned to intensive treatment with metformin. This part of the UKPDS became known as the Metformin Study, and the results were reported separately from the rest of the Glucose Control Study.2 The remaining 3867 patients nonoverweight and overweight ; were randomly assigned to conventional treatment with diet 30%, n 1138 ; or intensive treatment 70%, n 2729 ; with either a sulfonylurea n 1573 ; or insulin n 1156 ; .1 The nonbalanced randomization was chosen so that there were sufficient patients in the sulfonylurea group to allow comparison between those receiving the firstgeneration sulfonylurea chlorpropamide and those receiving the second-generation sulfonylurea glibenclamide.1.
KEY WORDS G-proteins; potassium channels; prostaglandin E1; ischemic preconditioning; signal transduction; ischemia-reperfusion injury ABSTRACT AIM: To investigate the effect of Gq 11 signaling pathway and ATP-sensitive potassium channels KATP channels ; on prostaglandin E1 PGE1 ; induced early and delay-preconditioning protection in rat hearts. METHODS: Two series of experiments were performed in Wistar rat hearts. In the first series of experiment, all rats were pretreated with PGE1 40 min or 23 h min before the experiment. Ischemia-reperfusion injury was induced by 30 min coronary artery occlusion followed by 90 min reperfusion. Hemodynamics, infarct size, and scores of ventricular arrhythmias were measured. The expression of Gq 11 protein in the heart was measured by Western blot analysis in the second series. RESULTS: Preconditioning with PGE1 25 g kg ; markedly reduced infarct size, left ventricular enddiastolic pressure, and scores of ventricular arrhythmia. The effect of PGE1 was significantly attenuated by glibenclamide 1 mg kg, ip ; , a nonselective KATP channel inhibitor. PGE1 caused a significant increase in the expression of Gq 11 protein. CONCLUSION: Activations of Gq 11 signal pathway and KATP channel played significant roles in the cardioprotection of PGE1 preconditioning in rat heart and might be an important mechanism of signal transduction pathway during the PGE1 preconditioning. INTRODUCTION Ischemic preconditioning IPC ; , a well-known phenomenon in which brief episodes of ischemia and reperfusion before a prolonged ischemic event limit myocardial cellular damage, has been shown to elicit both an acute and delayed phase of cardioprotection or a second window of protection[1]. The ATP-sensitive potassium channel has been suggested as an end-effector in the mechanism of ischemic preconditioning[2]. Recent studies show that the KATP channel mediates the myocardial protection induced by pharmacological agents such as adenosine agonist[3], opioids[4], flumazenil[5] and monophosphoryl lipid A MLA ; [6]. Hide et al[7] reported that PGE1 preconditioning reduced myocardial infarct size in the rabbit by activation of KATP channels . Gq 11, a member of G protein subunit plays an important role as a signal transduction pathway in protecting mechanism of ET-1 preconditioning and IPC[8]. The cardioprotective effects of PGE1 have been attributed to systemic and coronary vasodilation, inhibition of platelet aggregation and in particular, inhibition of neutrophil activation. However, PGE 1 has been suggested a cardioprotection induced by pharmacological preconditioning in rabbit heart and rat heart[7, 9] and itraconazole!
Fig. 6.40 Cystic papillary carcinoma A ; Fluid from cystic papillary carcinoma; numerous macrophages, many with pigment, some clustered; a few nuclei with longitudinal grooves; no well preserved epithelial cells Pap, HP B ; Tissue section from a cystic metastatic deposit in lymph node from same case; transition from intact neoplastic epithelium lining the cyst to exfoliated degenerating epithelial cells to `macrophages' with intracytoplasmic pigment HE, IP.
Glibenclamide pharmacy
1.1.2. CONSTIPATION AND FAECAL IMPACTION Non-drug treatment and ketoconazole. Click here for the gapyearshop, where you can buy sterile needle sets, sun protection gear, mosquito nets, iodine tablets, fist aid kits and more, because aspirin. Diagnosis Hypoglycaemia is due to an excessive level of insulin in blood and results in exceptionally low glucose values. Hypoglycaemia is defined as an event in which the typical symptoms of hypoglycaemia are combined with a plasma glucose concentration of 70 mg dl 3.9 mmol l ; 147. The symptoms are of both adrenergic and neuroglycopenic nature. Adrenergic symptoms include, among others, perspiration, shivering and palpitations. Neuroglycopenic phenomena include concentration problems, behavioural disorders, changes in consciousness and, ultimately, coma. The adrenergic disorders can be masked by the use of some drugs such as -blockers. In older patients, hypoglycaemia occasionally manifests in an unusual manner such as temporary paresis, CVA-like clinical symptoms, behavioural disorders or confusion. These neuroglycopenic pictures can sometimes be very misleading. Hypoglycaemia significantly occurs exclusively in patients taking sulfonylureas, glinides or insulin. When the treatment consists exclusively of diet, metformin, glitazones or alpha-glucosidase inhibitors, the risk of hypoglycaemia is more negligible. Because most Type 2 diabetics have insulin resistance, they are less at risk of hypoglycaemia than Type 1 diabetics who are generally highly sensitive to the action of exogenously administered insulin ; . For this reason, with Type 2 diabetes it is generally possible to aim for stricter glycaemic control than with Type 1 diabetes. Physicians must avoid being excessively careful with blood sugar lowering medication out of fear of hypoglycaemia. Factors that increase the risk of hypoglycaemia Skipping a meal Unusual physical effort Alcohol use, in particular without food sulfonylureas with long-term action especially glibenclamide ; Sulfonylurea use with impaired kidney function Sulfonylurea interference with other drugs sulphonamides, certain NSAIDs, fibrates, coumarin derivatives ; Insulin treatment and lamisil.
Glibenclamide on line
TO THE EDITOR: A 63-year-old woman presented with polyuria, polydipsia, lethargy and vomiting. Two weeks previously, she had been diagnosed as having diffuse scleroderma with possible interstitial lung disease, and had started taking 50 mg prednisolone daily. Her past history included diabetes, hypertension, hypercholesterolaemia and -thalassemia trait, and her other medications were metformin, glibenclamide, quinapril and amlodipine. Examination revealed blood pressure 150 60 mmHg, a loud second heart sound with no murmurs, and late inspiratory crepitations at lung bases. Her serum creatinine concentration was 270 mol L compared with 100 mol L two weeks previously ; and serum glucose concentration was 26.5 mmol L. Treatment by the admitting doctor included insulin, rehydration, and cessation of prednisolone given hyperglycaemia ; and quinapril secondary to acute renal impairment ; . She developed a fever and cough, with bilateral pneumonia, which was treated with intravenous ceftriaxone. Despite normotension, concern regarding scleroderma renal crisis SRC ; was raised. On Day 12 of admission, when renal failure had developed to the dialysisdependent level serum creatinine level, 690 mol L ; , quinapril was recommenced for its proposed renoprotective effect and haemodialysis was initiated. Microangiopathic haemolytic anaemia haemoglobin, 7.2 g L ; was diagnosed, with fragmented red blood cells Box ; . Several months later, she continues on haemodialysis three times a week. Renal biopsy was not performed given the clinical picture of diffuse scleroderma and recent and lansoprazole. In public session, the Board voted on May 16, 1998 upon Respondent's request, due to his admitted addiction, that the Board allow him to enter into a Stipulated Consent Order for temporary suspension of his license until such time it is determined that Respondent is healthy enough to be placed under a probationary order for monitoring and rehabilitation. The terms and conditions required in Respondent's Stipulated Consent Order for Suspension of License require random urine drug screens and abstention of all drugs and alcohol, unless prescribed by his treating physician. There was no induction of the cytochrome p450-system after chronic administration as shown with marker antipyrine and no interactions were observed after concomitant administration of pantoprazole with either antipyrine, diazepam, theophylline, digoxin, oral contraceptives, phenytoin, nifedipine, carbamazepine, diclofenac, metoprolol, glibenclamide, ethanol, and caffeine and levofloxacin. The best munis, the knowers of the truths of vedanta meditate on her as formless, immutable, stainless, omnipresent brahmâ devoid of all dharma. Perinorm clopra maxolon metoclopramide octamide reglan persol gel benzoyl peroxide benoxyl fostex oxy 5 panoxyl quinine quinamm quiphile surmontil trimipramine surmontil tarivid ofloxacin floxin tegretol atretol carbamazepine depitol epitol uniwarfin warfarin coumadin wymesone dexamethasone decadron dexameth dexone hexadrol zobid-d diclofenac voltaren zole miconazole daktarin fenoxene dibenzyline phenoxybenzamine urotone bethanechol chloride duvoid myotonachol urecholine phexin cephalexin biocef keflex keftab stemetil prochlorperazine compazine ventorlin albuterol salbutamol proventil ventolin volmax one-alpha alfacalcidol alfad proscar finasteride xenical orlistat adaferin differina adapalene angised glyceryl tnt arcalion flohale rotacap fluticasone flixotide flovent fluanxol depixol flupenthixole glez diabeta vlibenclamide glyburide glynase micronase lobate clobetasol temovate dermovate metolar betaloc lopressor metoprolol tartrate toprol metrotab-200 metrogyl flagyl metronidazole okabax md generic vioxx rofecoxib paraxin chloramphenicol thyrox levothyroxine levothroid levoxine levoxyl synthroid unithroid warning : main popular ; : failed to open stream: no such file or directory in home virtual site95 fst var site on line 102 warning : main ; : failed opening 'popular ' for inclusion include path ' and lexapro and glibenclamide. Hepatitis Vaccine There is a vaccine that can help prevent you from getting hepatitis. Your doctor may order this vaccine for you. The vaccine makes your body produce antibodies that kill the hepatitis virus. The vaccine is a total of four injections at different times; one shot at the beginning, one shot after one month, another after two months, and another shot six months from the first. After all the shots are completed, your blood will be checked to see if you have the antibodies. The medicine does not produce antibodies in everyone and if you are a kidney patient, you have a greater chance of not developing antibodies. If you do not develop antibodies, your doctor will order another series of shots for you. If you have more questions about this medicine or if you want to get it, talk with your doctor or nurse.
Merck & Co., Inc. helps address HIV AIDS in the Caribbean thro ugh education, prevention, treatment, care and advocacy, in partnership with people living with HIV AIDS, caregivers, the business community and the public sector. Merck has provided more than $500, 000 to Caribbean NGOs to address HIV AIDS, funding initiatives to assist people living with HIV AIDS, helping health care professionals improve treatment and care, enco uraging private and public sector responses and addressing stigma and discrimination. In 2005-06, Merck funded the Agua Buena Human Rights Association, which advocates treatment, access and respect for human rights in the Dominican Republic and other co untries, via meetings, statements, articles, reports and conferences. It also educates on HIV AIDS and TB issues. In 2004-5, Merck gave the Jamaica AIDS Support community co unseling and care gro up a $40, 000 grant and USAID will provide technical assistance and related program support over the next five years. Merck, the U.S. Agency for International Development, the University of the West Indies, the University of Washington and others provide HIV training for health care providers thro ugh the Caribbean HIV AIDS Regional Training Network CHART ; , centers in Jamaica, Bahamas, Haiti and Barbados. Merck made CHART a $150, 000 grant in 2005 and in-kind donation and technical assistance continued into 2006. The University of the West Indies HIV AIDS Response Program used a $51, 000 grant from Merck to survey 480 pharmacists in Jamaica, Bahamas, Barbados and St. Lucia to assess attitudes to HIV AIDS patients. Results were passed to CHART, to help direct pharmacist training. To launch the Jamaica Business Co uncil on HIV AIDS in 2006, the AIDS Responsibility Project and F utures Gro up surveyed 23 companies. It fo und that 61% did not have HIV policies and that discrimination was significant. Merck and USAID each granted $50, 000 to support this survey. Merck also provided funding in 2005 for the Caribbean Association for Industry and Commerce's Pan-Caribbean Executive Forum on HIV AIDS and is committed to provide ongoing technical expertise and loratadine.
Hypoglycaemia is a serious side effect of therapy which can rarely ; be fatal. Hypoglycaemia is less common in people treated with sulphonylureas than in those taking insulin, but may be more prolonged and more severe, particularly when associated with substantial alcohol consumption. Hlibenclamide is particularly prone to causing hypoglycaemia and should not be used in elderly people. All patients started on sulphonylurea drugs should be warned about the possibility of hypoglycaemia and told to discontinue the tablets and seek medical advice should it occur. The symptoms and signs of hypoglycaemia can be variable. A high index of suspicion is often required. The primary endpoint, mean change in HbA1c from baseline to week 52, in the intention-totreat ITT ; population using last observation carried forward LOCF ; for missing data was analysed via an analysis of covariance ANCOVA ; model with baseline HbA1c as covariate. Non-inferiority, the primary analysis, was defined as an upper limit of two-sided 90% confidence intervals CI ; for the difference between pioglitazone and gliclazide in mean change from baseline HbA1c of less than 0.2%. Non-inferiority of pioglitazone to gliclazide was demonstrated, with 52-week mean HbA1c reductions of 1.43% and 1.35%, respectively, and estimated treatment difference 90% CI ; of -0.08% -0.18%, 0.02% ; . Mean reduction in fasting plasma glucose FPG ; from baseline to week 52 was significantly greater with pioglitazone compared to gliclazide: -2.4 versus -2.0 mmol L, with an estimated treatment difference 95% CI ; of -0.4 mmol L -0.7, -0.1 ; . In this trial, mean total cholesterol, low-density lipoprotein LDL ; -cholesterol and high-density lipoprotein HDL ; -cholesterol increased from baseline to 52 weeks in the pioglitazone group. In the gliclazide group, HDL-cholesterol increased, however, total cholesterol and LDLcholesterol decreased, with differences between groups significant for all variables. Mean total cholesterol: HDL-cholesterol ratio decreased significantly more with pioglitazone than gliclazide: -0.8 versus -0.6. Triglycerides were reduced in both groups, with no significant differences between them. A one-year double-blind extension to this trial included 567 patients who had successfully completed the initial study at a centre within the subgroup of centres participating in the extension study. They were maintained throughout the extension study on the same dose of active treatment that they had received during the initial study. The primary analysis, time to treatment failure, defined as first measurement of HbA1c 8% after week 24, was assessed via a log rank test. At week 24, the proportions of patients classed as treatment failures were similar in both groups, but were greater with gliclazide from this point, with a significant difference between groups in survival distributions through to week 104. A 26-week double-blind trial recruited 263 patients, aged 35-75 years, with body mass index BMI ; 25 kg m 2, who had type 2 diabetes, with HbA1c 7.5-11.5% and FPG 7.8-13.9 mmol L after four to eight weeks' of placebo. They were randomised to placebo, pioglitazone 30mg or glivenclamide 2.5mg daily, with doses of active treatments increased after eight weeks to 45mg and 5mg, respectively, if HbA1c had not decreased by 0.3%. Comparison of active agents a secondary analysis ; by ANCOVA indicated that glibenclamde decreased HbA1c and FPG more than pioglitazone, but differences were not significant. Estimated between treatment difference 95% CI ; for HbA1c was 0.27% -0.02%, 0.55% ; . The data detailed above were provided in the original submission to the Scottish Medicines Consortium SMC ; . The resubmission contained additional data from a trial comparing pioglitazone with rosiglitazone and a meta-analysis of randomised placebo-controlled trials of these drugs. A double-blind trial recruited 802 patients, aged at least 35 years with type 2 diabetes and dyslipidaemia, defined as fasting triglyceride 150 and 600 mg dL and LDL-C 130 mg dL, who had previously been treated with diet and exercise and or one oral hypoglycaemic drug. After a four-week placebo wash-out patients were randomised to pioglitazone 30mg once daily or rosiglitazone 4mg once daily, with doses increased at 12 weeks in the respective groups to 45mg once daily and 4mg twice daily and continued to week 24. Efficacy variables were analysed by ANCOVA with LOCF. Mean changes from baseline to 24 weeks in HbA1c were comparable in the respective groups: -0.7% and -0.6%. This was a secondary endpoint in a trial designed primarily to investigate effects on triglycerides. Pioglitazone was associated with significant improvements from baseline to week 24 in mean triglycerides and HDLcholesterol compared to rosiglitazone, although HDL-cholesterol was significantly improved.
Concentration dependent and the mean data Fig. 5B ; suggests a half maximal inhibition around 150-200 M glibenclamide. The observed rundown of channel activity is characteristic of Kir1.1b behaviour in excised patches 21 ; . 50 glibenclamide inhibits 28.2 4.5% n 6; N 2 ; , 0.2 mM inhibits 54.1 3.9 % n 15; N 2 ; and 0.5 mM inhibits 74.9 8.1% n 5; N 2 ; of the current in control drug free ; solution. These results clearly show that high concentrations of glibenclamide can cause significant inhibition of Kir1.1b currents. Furthermore, the effect is rapid within seconds ; and reversible.
The rat thoracic aorta. The possible mechanism of action was also studied pharmacologically. Materials and Methods Animals Male Wistar-Imamichi rats 8-9 weeks old; body weight, 250-330 g ; were used in all experiments. All animals were maintained at a controlled temperature 222C ; under a regular light dark cycle light period: 7: 00 to 19: 00 h ; with free access to food and water. All experiments were conducted in accordance with the guidelines of the Physiological Society of Japan regarding the care of experimental animals. Drugs For in vivo experiments, bovine lactoferrin BLF; MW approximately 78000; Tatua, Morrinsville, New Zealand ; , Bovine serum albumin BSA; MW approximately 66000; Sigma, Tokyo, Japan ; , naloxone hydrochloride Sigma ; , naloxone methiodide Sigma ; , morphine hydrochloride Sankyo, Tokyo, Japan ; , diclofenac Sigma ; , acetylcholine chloride ACh; Daiichi, Tokyo Japan ; , atropine sulfate atropine; Fuso, Osaka, Japan ; , NG-nitro-L-arginine methyl hydrochloride L-NAME; Sigma ; , and NG-nitro-D-arginine methyl ester hydrochloride D-NAME; Sigma ; were dissolved in saline solution for administration at a volume of 1 ml kg. For in vitro experiments, BLF, ACh, L-NAME, D-NAME, L-phenylephrine hydrochloride Sigma ; , and sodium nitroprusside dihydrate SNP, Sigma ; were dissolved in distilled water, and glibenclamide Wako, Osaka, Japan ; and pinacidil Sigma ; were dissolved in DMSO at the concentration of 10 mM and diluted with distilled water to the desired concentrations. The purity of BLF 95.3% ; was certificated by Tatua. We also performed SDS-PAGE on BLF to ensure that no other protein was present in the preparation data not shown ; . In vivo experiment Measurement of blood pressure and heart rate Rats were initially anesthetized with intraperitoneal injection of urethane 1g kg, Sigma, Tokyo, Japan ; . Supplemental doses were given through a jugular intravenous catheter whenever needed. The trachea was cannulated. The system was equipped with Class VP series version 6.12 software. Chromatographic conditions: The mobile phase consisted of 20 mM monobasic potassium dihydrogen orthophosphate in water, which was adjusted to pH 3.5 with phosphoric acid, and acetonitrile in the proportion of 60: 40 v v. The mobile phase was filtered through 0.22 m membrane filter Sartorius, Germany ; . The flow rate was 1 ml min and the column effluent was monitored at 225 nm. The total run time of the method was set at 20 min. The peaks were well resolved and the retention time for glibenclamide and glipizide internal standard ; was 9.60 and 5.96 min respectively. No interfering peaks were observed at the retention time of glibenclamide and glipizide. Standard Solutions: A standard stock solution of glibenclamide 100 g ml ; was prepared in acetonitrile. The calibration curve standard solutions were prepared by adding known amount of glibenclamide concentrations: 1-20 g ml ; and glipizide, an internal standard 1 g ml ; , blank plasma. Extraction procedure: A volume of 0.1 ml of blank mouse plasma and 0.1 ml of 0.1 N hydrochloric acid were mixed thoroughly. The plasma was spiked with standard glibenclamide and glipizide solutions to yield concentrations of 1-20 g ml of glibenclamide and 1 g ml glipizide, respectively. Then the mixture was gently shaken for 3 min and then it was added with 5 ml of benzene in a 20 glass tube. The tube was gently shaken using cyclomixer Remi cyclomixer, Mumbai ; for 5 min and centrifuged Remi Centrifuge, Mumbai, India ; for 10 min at 3000 rpm. After centrifugation, the organic phase was transferred into a conical tube for evaporation to dryness under nitrogen. The residue was dissolved in 0.1 ml of equilibrated mobile phase by vortexing. An aliquot of 20 l was injected into the chromatograph. Calibration curve: Calibration curve was obtained by plotting peak area ratios of glibenclamide to glipizide y-axis ; against glibenclamide concentration x-axis ; . The pharmacokinetic parameters were calculated using noncompartmental pharmacokinetics data analysis software, PK Solutions 2.0TM and glucovance.